Background The non-invasive determination of the asialoglycoprotein receptor (ASGR) expression on liver tissue might be a predictive parameter helping to prevent severe liver diseases as well as liver failure after surgery and transplantation. Recently, we introduced [68Ga]Ga-NODAGA-NonaLysan, which showed even a higher liver uptake as the gold standard [99mTc]Tc-Galactosyl Serum Albumin. Here we describe the synthesis and evaluation of two 18F-labeled analogues, prepared using either a SiFA- or an AlF-labeling approach. Results The two precursors could be produced in high purity (> 97%). Both labeling strategies allowed production of the radiopharmaceuticals in high radiochemical purity. The radiochemical yield was up to 58% d.c. for [18F]SiFA-NonaLysan and up to 71% d.c. for Al[18F]F-NOTA-6-Ahx-NonaLysan. In vitro evaluation showed high stability in PBS and human serum. Both compounds possessed nanomolar affinity for the ASGR (IC50 = 0.9 ± 1.1 nM and 3.0 ± 2.1 nM, respectively). However, based on the design differences, Al[18F]F-NOTA-6-Ahx-NonaLysan showed a 100-fold lower logD as found for [18F]SiFA-NonaLysan. In consequence, the protein binding effect was higher for [18F]SiFA-NonaLysan, and the lipophilic character drastically affected the pharmacokinetic pattern. Initial liver uptake was higher for [18F]SiFA-NonaLysan (100% ID/g vs. 70% ID/g 10 min p.i.), but was accompanied by a quick organ washout and activity accumulation in the intestines. A much better activity retention was observed for Al[18F]F-NOTA-6-Ahx-NonaLysan. PET/MR imaging confirmed the differences in liver uptake, with a higher retention found for the latter. Based on the receptor function, both compounds are internalized and subsequently degraded. For Al[18F]F-NOTA-6-Ahx-NonaLysan, all radioactive liver metabolites found were more hydrophilic than the intact compound. For [18F]SiFA-NonaLysan, the contrary is the case, and almost all liver metabolites were more lipophilic. The hepatobiliary excretion of these metabolites prevents a stable activity retention in the hepatic tissue. Conclusion In this study, we successfully synthesized two new 18F-labeled radiopharmaceuticals targeting the ASGR. The in vivo evaluation revealed two different pharmacokinetic profiles. Extremely high uptake was found for [18F]SiFA-NonaLysan in the initial phase, followed by a quick organ washout. Al[18F]F-NOTA-6-Ahx-NonaLysan showed a lower but more stable activity retention in the liver, indicating advantageous imaging properties.

Comparison of two ¹⁸F-fluorinated glycopeptides for PET imaging of the functional liver mass

期刊论文
出版模式：

开放获取
发表日期：

2026年4月4日

查看全文

Maximilian A. Zierke,
Katharina Hofer,
Kimia Samadikhah,
Christine Rangger,
Carmen Wängler,
Björn Wängler,
Anna Junker,
Andreas M. Schmid,
Roland Haubner

摘要

Background

The non-invasive determination of the asialoglycoprotein receptor (ASGR) expression on liver tissue might be a predictive parameter helping to prevent severe liver diseases as well as liver failure after surgery and transplantation. Recently, we introduced [⁶⁸Ga]Ga-NODAGA-NonaLysan, which showed even a higher liver uptake as the gold standard [^99mTc]Tc-Galactosyl Serum Albumin. Here we describe the synthesis and evaluation of two ¹⁸F-labeled analogues, prepared using either a SiFA- or an AlF-labeling approach.

Results

The two precursors could be produced in high purity (> 97%). Both labeling strategies allowed production of the radiopharmaceuticals in high radiochemical purity. The radiochemical yield was up to 58% d.c. for [¹⁸F]SiFA-NonaLysan and up to 71% d.c. for Al[¹⁸F]F-NOTA-6-Ahx-NonaLysan. In vitro evaluation showed high stability in PBS and human serum. Both compounds possessed nanomolar affinity for the ASGR (IC₅₀ = 0.9 ± 1.1 nM and 3.0 ± 2.1 nM, respectively). However, based on the design differences, Al[¹⁸F]F-NOTA-6-Ahx-NonaLysan showed a 100-fold lower logD as found for [¹⁸F]SiFA-NonaLysan. In consequence, the protein binding effect was higher for [¹⁸F]SiFA-NonaLysan, and the lipophilic character drastically affected the pharmacokinetic pattern. Initial liver uptake was higher for [¹⁸F]SiFA-NonaLysan (100% ID/g vs. 70% ID/g 10 min p.i.), but was accompanied by a quick organ washout and activity accumulation in the intestines. A much better activity retention was observed for Al[¹⁸F]F-NOTA-6-Ahx-NonaLysan. PET/MR imaging confirmed the differences in liver uptake, with a higher retention found for the latter. Based on the receptor function, both compounds are internalized and subsequently degraded. For Al[¹⁸F]F-NOTA-6-Ahx-NonaLysan, all radioactive liver metabolites found were more hydrophilic than the intact compound. For [¹⁸F]SiFA-NonaLysan, the contrary is the case, and almost all liver metabolites were more lipophilic. The hepatobiliary excretion of these metabolites prevents a stable activity retention in the hepatic tissue.

Conclusion

In this study, we successfully synthesized two new ¹⁸F-labeled radiopharmaceuticals targeting the ASGR. The in vivo evaluation revealed two different pharmacokinetic profiles. Extremely high uptake was found for [¹⁸F]SiFA-NonaLysan in the initial phase, followed by a quick organ washout. Al[¹⁸F]F-NOTA-6-Ahx-NonaLysan showed a lower but more stable activity retention in the liver, indicating advantageous imaging properties.

Comparison of two 18F-fluorinated glycopeptides for PET imaging of the functional liver mass

摘要

Comparison of two ¹⁸F-fluorinated glycopeptides for PET imaging of the functional liver mass